Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

A randomized controlled trial of genotype-based Coumadin initiation.

Burmester JK, Berg RL, Yale SH, Rottscheit CM, Glurich IE, Schmelzer JR, Caldwell MD.

Genet Med. 2011 Jun;13(6):509-18. doi: 10.1097/GIM.0b013e31820ad77d.

PMID:
21423021
2.

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.

Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC.

Pediatr Blood Cancer. 2014 Jun;61(6):1055-62. doi: 10.1002/pbc.24932. Epub 2014 Jan 29.

PMID:
24474498
3.

Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.

Ma C, Zhang Y, Xu Q, Yang J, Zhang Y, Gao L, Xu B, Wang H, Li Y, Lu C, Yin T.

Int J Hematol. 2012 Dec;96(6):719-28. doi: 10.1007/s12185-012-1205-8. Epub 2012 Oct 27.

PMID:
23104259
4.

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL.

J Thromb Thrombolysis. 2006 Dec;22(3):191-7.

PMID:
17111199
5.

Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.

Özer M, Demirci Y, Hizel C, Sarikaya S, Karalti İ, Kaspar Ç, Alpan S, Genç E.

Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):209-14. doi: 10.1111/bcpt.12024. Epub 2012 Dec 6.

6.

Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.

Daly AK.

Arch Toxicol. 2013 Mar;87(3):407-20. doi: 10.1007/s00204-013-1013-9. Epub 2013 Feb 2. Review.

PMID:
23376975
7.

Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.

Teh LK, Langmia IM, Fazleen Haslinda MH, Ngow HA, Roziah MJ, Harun R, Zakaria ZA, Salleh MZ.

J Clin Pharm Ther. 2012 Apr;37(2):232-6. doi: 10.1111/j.1365-2710.2011.01262.x. Epub 2011 Apr 20.

PMID:
21507031
8.

Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.

Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE, Goldhaber SZ, King CR, Giri T, McLeod HL, Glynn RJ, Gage BF.

J Thromb Haemost. 2010 Jan;8(1):95-100. doi: 10.1111/j.1538-7836.2009.03677.x. Epub 2009 Oct 30.

9.

Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation.

Xu Q, Xu B, Zhang Y, Yang J, Gao L, Zhang Y, Wang H, Lu C, Zhao Y, Yin T.

Thromb Haemost. 2012 Dec;108(6):1132-40. doi: 10.1160/TH12-05-0362. Epub 2012 Sep 26.

PMID:
23015069
10.

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL.

Thromb Haemost. 2008 Aug;100(2):229-39.

PMID:
18690342
11.

CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.

Nakamura K, Obayashi K, Araki T, Aomori T, Fujita Y, Okada Y, Kurabayashi M, Hasegawa A, Ohmori S, Nakamura T, Yamamoto K.

J Clin Pharm Ther. 2012 Aug;37(4):481-5. doi: 10.1111/j.1365-2710.2011.01317.x. Epub 2011 Dec 16.

PMID:
22172097
12.

A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.

Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y, Yu F.

Thromb Haemost. 2012 Jun;107(6):1083-91. doi: 10.1160/TH11-12-0848. Epub 2012 Apr 26.

PMID:
22534826
13.

Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.

Kadian-Dodov DL, van der Zee SA, Scott SA, Peter I, Martis S, Doheny DO, Rothlauf EB, Lubitz SA, Desnick RJ, Halperin JL.

Vasc Med. 2013 Oct;18(5):290-7. doi: 10.1177/1358863X13503193. Epub 2013 Sep 12.

PMID:
24029542
14.

Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.

Gong IY, Schwarz UI, Crown N, Dresser GK, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Wells PS, Kim RB, Tirona RG.

PLoS One. 2011;6(11):e27808. doi: 10.1371/journal.pone.0027808. Epub 2011 Nov 16.

15.

VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.

Biss TT, Avery PJ, Brandão LR, Chalmers EA, Williams MD, Grainger JD, Leathart JB, Hanley JP, Daly AK, Kamali F.

Blood. 2012 Jan 19;119(3):868-73. doi: 10.1182/blood-2011-08-372722. Epub 2011 Oct 18.

16.

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement.

Moreau C, Bajolle F, Siguret V, Lasne D, Golmard JL, Elie C, Beaune P, Cheurfi R, Bonnet D, Loriot MA.

Blood. 2012 Jan 19;119(3):861-7. doi: 10.1182/blood-2011-07-365502. Epub 2011 Nov 30.

17.

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC.

Clin Pharmacol Ther. 2006 Oct;80(4):346-55.

PMID:
17015052
18.

Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.

Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary O.

Int J Clin Pharm. 2012 Dec;34(6):837-44. doi: 10.1007/s11096-012-9678-3. Epub 2012 Jul 27.

PMID:
22851439
19.

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ.

Br J Clin Pharmacol. 2010 Aug;70(2):234-40. doi: 10.1111/j.1365-2125.2010.03698.x.

20.

Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.

Choi JR, Kim JO, Kang DR, Yoon SA, Shin JY, Zhang X, Roh MO, Hong HJ, Wang YP, Jo KH, Lee KS, Yun HJ, Oh YS, Yoo KD, Jeon HG, Lee YS, Kang TS, Park HJ, Chung MW, Kang JH.

J Hum Genet. 2011 Apr;56(4):290-5. doi: 10.1038/jhg.2011.4. Epub 2011 Feb 17.

PMID:
21326313

Supplemental Content

Support Center